Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Grandner, Michael
Fernandez, Fabian
Mason, Brooke Jordan
Pau, Stanley K. H.
Abrégé
Methods and devices are described that rely on interference filter designs to provide a precise and granular spectral behavior by allowing emissions of circadian-active blue and green light to reach a viewer. An example wearable device includes one or more windows positioned to allow light from a light source to propagate toward a position of a wearer's eyes, and a spectral filter that includes a coating positioned on one or more sections of the one or more windows. The spectral filter includes a multi-layer stack of dielectric material with alternate high and low indices of refraction. The number of the layers and a thickness of each layer are selected to provide designed transmission and blocking characteristics to allow circadian-active spectra to reach the wearer's eyes while blocking spectral content other than the circadian-active spectra. The designed transmission and blocking characteristics include a contiguous transmission region and two contiguous blocking regions.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Hua, Hong
Wilson, Austin
Abrégé
An occlusion-capable viewing device includes an imaging lens, a collimating lens, and a virtual display module, and between the imaging lens and the collimating lens, an image inverter, and a spatial light modulator. The imaging lens projects a first inverted image of a scene on to an entrance surface of the image inverter. The image inverter rotates the first inverted image to yield a first upright image. The spatial light modulator attenuates a first image-region of the first upright image to produce a modulated optical beam. The virtual display module includes a display device and a light combiner, which combines (i) the collimated optical beam and (ii) illumination emitted by the display device to yield an occluded image.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Zenhausern, Frederic
Lacombe, Jerome
Helton, James
Dunn, Sean Edward
Barrett, Matthew W.
Abrégé
Provided are devices that simulate in vivo conditions of a biological system and that are modular for reliable assembly and disassembly to improve handling of biological systems and subsequent analysis and experimentation therein. A center block having a fluidic network to support a biological material is in fluidic connection with a pair of side channels. With this platform, biological material may be supported and exposed to a plurality of well-defined fluidic characteristics and compositions.
B67D 7/08 - Aménagements des dispositifs pour commander, indiquer, mesurer ou enregistrer la quantité ou le prix du liquide transféré
C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Fernandez, Fabian
Mason, Brooke Jordan
Grandner, Michael
Pau, Stanley K. H.
Abrégé
Methods and devices are described that relate to spectral filters and associated eyewear that are specifically designed to mitigate the disruptive effects of electric lighting on the circadian clock that can cause sleep deprivation and other physiological and psychological maladies. An example wearable device for viewing a real or virtual environment includes one or more windows positioned and a spectral filter that comprises a coating positioned on one or more sections of the one or more windows. The spectral filter includes a multi-layer stack of dielectric material with alternate high and low indices of refraction. The number of the layers and a thickness of each layer are selected to provide designed transmission and blocking characteristics to block circadian-rhythm-disruptive spectra from reaching the wearer's eyes while providing viewability of the real or virtual environment by allowing light outside of the circadian-rhythm-disruptive spectra to reach the wearer's eyes.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Su, Judith
Li, Cheng
Abrégé
A temperature-corrected biochemical sensor includes an optical resonator disposed proximate a single-mode optical fiber, the optical resonator being optically coupled to the optical fiber to receive optical whispering-gallery output light; a sensor detection system arranged to receive and detect the optical whispering-gallery output light to provide sensor signals; a temperature-correcting optical system to provide a reference beam of light to be combined at least partially coherently with a return light from the resonator to provide an interference light and convert, the interference light to temperature-correction signals; a data storage device comprising temperature calibration data for at least the optical fiber and the optical resonator; and a data processing system to calculate at least one physical property of a particle in contact with the optical resonator using the sensor signals such that the calculated physical property is temperature corrected using the temperature calibration data and the temperature-correction signals.
G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
6.
ARTIFICIAL THREE-DIMENSIONAL (3D) CRYSTALS AND USE OF THE SAME AS AN EDUCATIONAL TOOL
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Englar, Ryane
Beasley, Eric
Abrégé
Provided herein are educational models that include a substrate and one or more 3D printed structures mounted or affixed thereon, where the one or more 3D printed structures resemble crystals, normal and/or abnormal cells, or casts found in a biofluid. Also provided herein are educational models that include one or more 3D printed structures contained (for example, dispersed or suspended) in a carrier, where the one or more 3D printed structures resemble crystals, normal and/or abnormal cells, or casts found in a biofluid. Also provided herein are kits having a plurality of educational models, where each of the educational model is individually identifiable, and an answer key or guide that provides an identification of each 3D printed structure contained in each of the plurality of individually identifiable educational models. The 3D printed structures can be dimensioned for viewing with the naked eye or can be dimensioned for viewing under magnification.
G09B 23/26 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour l'étude des structures moléculairesModèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la cristallographie
7.
COMPOSITIONS AND METHODS FOR DELIVERY OF IL-2 AND ANTI-IL-2 FOR TREATMENT OF RHEUMATOID ARTHRITIS
Arizona Board of Regents on behalf of Arizona State University (USA)
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Acharya, Abhinav
Wu, Hsin-Jung (joyce)
Abrégé
The present invention provides a sustained drug release system comprising IL-2 and anti-IL-2 incorporated into a thermosensitive hydrogel that is engineered to be in liquid form at low temperatures for delivery, but form a hydrogel at physiological body temperatures to act as a sustained release platform. The thermostable hydrogel solution slowly releases IL-2 and anti-IL-2 to provide optimal concentrations for effective treatment of autoimmune diseases.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Allen, John
Lane, Richard
Roveda, Janet
Chang, Ping
Wung, Shu-Fen
Abrégé
Disclosed is a heart rate monitoring system containing a machine learning platform containing self-learning and/or personalizable algorithms capable of detecting and filtering out artifacts in signals indicative of an individual's heart rate, such signals generated from one or more electrocardiogram sensors. The self-learning and/or personalizable algorithms are updated periodically. Accordingly, the machine learning platform improves its accuracy in detecting and/or rejecting/filtering out artifacts and/or becomes more personalized as further signals indicative of an individual's heart rate are processed. The machine learning platform performs detection and filtering out of artifacts via dimension reduction algorithms. The system further contains a first algorithm for real time measurement of heart rate variability (HRV). Also disclosed is a heart rate monitoring method that implements a heart rate monitoring system disclosed herein. The heart rate monitoring system and method can partition physiological components of HRV from other non-physiological components, particularly physical activity and/or breathing.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
DIGNITY HEALTH (USA)
Inventeur(s)
Patwardhan, Amol
Porreca, Frank
Romanovsky, Andrej
Abrégé
Compositions and methods are provided for treating, ameliorating, and preventing anesthesia-induced hypothermia and/or postsurgical associated hyperalgesia in a mammalian subject comprising administering to the subject an effective amount of an ion channel TRPV1 inhibitor.
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61M 16/01 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p. ex. ventilateursTubes trachéaux spécialement conçus pour l'anesthésie
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
10.
FLYBACK ECHO-PLANAR IMAGING WITH EMBEDDED DIXON SCHEME (FEEDS)
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Chen, Nan-Kuei
Abrégé
An MRI protocol employing a new flyback echo-planar imaging (EPI) pulse sequence configured to acquire flyback EPI data in which chemical-shift artifact and magnetic field inhomogeneity are inherently encoded and a novel flyback EPI reconstructive image transformation procedure resulting in generating EPI images(s) that are not only substantially free from the Nyquist artifact of the MRI process but also substantially free from the chemical-shift artifact and geometric distortion of the MRI process.
G01R 33/561 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.-à-d. systèmes d'acquisition rapide, p. ex. utilisant des séquences d'impulsions écho-planar
G01R 33/565 - Correction de distorsions d'image, p. ex. dues à des inhomogénéités de champ magnétique
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G01R 33/485 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p. ex. spectroscopie in vivo basés sur l'information de déplacement chimique
G01R 33/50 - Systèmes d'imagerie RMN basés sur la détermination des temps de relaxation
11.
POLYMERIC VENOUS VALVE SYSTEMS AND METHODS OF MAKING AND USING THEREOF
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Slepian, Marvin J.
Bluestein, Danny
Kovarovik, Brandon
Abrégé
Polymeric venous valve systems having a supportive frame embedded in a polymeric sleeve and a plurality of polymeric leaflets forming a continuum with the polymeric sleeve are described herein. Methods of making and using such polymeric venous valve systems are also described. The polymeric venous valve systems are well-suited for use in low pressure and low shear venous environments.
A61F 2/82 - Dispositifs maintenant le passage ou évitant l’affaissement de structures tubulaires du corps, p. ex. stents
12.
USE OF A DISPERSIVE OPTICAL ELEMENT AS A SPECTRAL RECOMBINER FOR AN ADVANCED VOLUME HOLOGRAM FILTER (AVHF) AND OPTICAL IMAGING SYSTEMS EMPLOYING SUCH FILTER
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Suzuki, Andrew
Blanche, Pierre Alexandre
Alcaraz, Pedro Enrique
Nero, Gregory Michael
Abrégé
Addition of a light-recombiner in the form of a diffraction grating to an advanced-volume-hologram filter system (conventionally containing only a pre-disperser diffraction grating and a volume holographic filter VHF configured as a volume Bragg grating, VBG) demonstrated recollimation and spatial overlap of light components at different wavelengths in addition to the spectral bandwidth optimization and signal-to-noise improvement. Here, the wide spectral bandwidth is ensured by the angular Bragg-matching of the pre-disperser with the VBG. The signal-to-noise improvement is obtained by the wavefront selectivity of the VBG. The cancellation of the spectral dispersion is achieved by the light-recombiner. Utilization of a light-recombiner in the form of a diffraction grating as opposed to another dispersive optic such as an optical prism additionally eliminates the potential for spatial chirp that normally reduces the usability of the conventional AVHF system in optical imaging applications.
G03H 1/26 - Procédés ou appareils adaptés spécialement pour produire des hologrammes multiples ou pour en obtenir des images, p. ex. procédés pour l'holographie à plusieurs couleurs
13.
SMALL MOLECULE ADRENORECEPTOR ANTAGONISTS AND USES THEREOF
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Daryaei, Iman
Streicher, John
Schwarz, Abigail
Abrégé
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperdinyl-formamide (or similar) structure which function as adrenoreceptor antagonists, and their use as therapeutics for the treatment and/or prevention of pain and related conditions. In addition, the present invention provides compositions comprising a mixture of opioid receptor agonist compounds and such adrenoreceptor antagonists for the treatment and/or prevention of pain and related conditions.
A61K 31/4468 - Pipéridines non condensées, p. ex. pipérocaïne ayant un atome d'azote lié directement en position 4, p. ex. clébopride, fentanyl
A61K 31/4525 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
14.
METHODS AND COMPOSITIONS FOR TREATING CARDIOMYOPATHY
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Pappas, Christopher
Abrégé
Nonsense-mediated mRNA decay, a cellular mechanism that eliminates mRNAs containing premature termination codons, underlies the loss of mutant protein caused by two independent disease-causing mutations (e.g., cardiomyopathy) in LMOD2. To counteract this, steric-blocking oligonucleotides (SBOs) were developed to obstruct the deposition of the exon junction complex, thereby preventing nonsense-mediated mRNA decay of the mutant LMOD2 transcripts and restoring mutant protein expression. This approach forms the basis for methods of treating subjects suffering from cardiomyopathy using these SBOs.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Schwiegerling, James T.
Abrégé
A diffractive multifocal lens is disclosed, comprising an optical element having at least one diffractive surface, the surface profile comprising a plurality of annular concentric zones. The optical thickness of the surface profile changes monotonically with radius within each zone, while a distinct step in optical thickness at the junction between adjacent zones defines a step height. The step heights for respective zones may differ from one zone to another periodically so as to tailor diffraction order efficiencies of the optical element. In one example of a trifocal lens, step heights alternate between two values, the even-numbered step heights being lower than the odd-numbered step heights. By plotting a topographical representation of the diffraction efficiencies resulting from such a surface profile, step heights may be optimized to direct a desired level of light power into the diffraction orders corresponding to near, intermediate, and distance vision, thereby optimizing the lens performance.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
EMORY UNIVERSITY (USA)
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Hecker, Louise
Gokhale, Vijay
Abrégé
The present disclosure relates to compounds, compositions, and methods for inhibiting Nox4 signaling. Also described are methods of treating fibrotic disorders (e.g., pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis) and acute respiratory distress syndrome (ARDS) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Herbst-Kralovetz, Melissa M.
Laniewski, Pawel
Abrégé
Endometrial cancer (EC) is the most common gynecologic cancer in developed countries and the fourth most common cancer affecting women in the US. In contrast to other cancers, rates of EC continue to rise, and there are indications that social determinants of health and race and/or ethnicity contribute to risk. Thus, the methods described herein provide a non-invasive means of measuring protein biomarkers in the local cervicovaginal microenvironment. These novel biomarkers may be used for diagnosing and/or predicting women that are “at risk” for the development and progression of endometrial cancer (EC; e.g., EC type 1). Specifically, the methods herein may include obtaining a sample (e.g., CVL, vaginal swabs, or secretions) from a patient and producing a profile of at least five or more protein biomarkers from the collected sample.
ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Song, Yang
Fan, Changpeng
Abrégé
Systems and methods for determining information representing an amount of an indicator of a soil trait based on a machine learning engine, and systems and methods for training the machine learning engine are described. An example method includes obtaining values of a plurality of environmental factors relating to a location, and determining the information representing the amount of the indicator by inputting the values of the plurality of environmental factors into a machine learning engine. The machine learning engine is trained using sample datasets each of which includes values of at least a portion of the plurality of environmental factors of a sample site and information representing an amount of the indicator of the sample site.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Kupinski, Meredith
Shanks, Kira
Abrégé
Methods and systems for differentiating different phases of ice-to-water and water-to-ice transitions based on polarimetric values are described. One example method for discriminating ice from melting ice includes obtaining measured polarimetric values for a sample. The measured values are wavelength-resolved such that each of the measured values corresponds to a particular wavelength, or a particular range of wavelengths, in a long-wave infrared (LWIR) region, and the measured polarimetric values span a plurality of wavelengths, or ranges of wavelengths, within the LWIR region. The method further includes determining a plurality of wavelength-resolved degree of polarization (DoP) values based on the measured polarimetric values, comparing the plurality of wavelength-resolved DoP values to a reference set of DoP values, and distinguishing ice from melting ice based on the comparison to the reference set of DoP values.
G01N 21/3554 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour la détermination de la teneur en eau
G01N 21/3563 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de solidesPréparation des échantillons à cet effet
G01N 21/3577 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de liquides, p. ex. l'eau polluée
G01N 21/3581 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge lointainCouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant un rayonnement térahertz
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Debbins, Michael
Schuler, Tristan
Goolsby, Davis
Crest, Joshua
Thangavelautham, Jekan
Abrégé
Solar balloons are a simple and lightweight option for aerial exploration and meteorological data collection both terrestrially and on other planets. By using lightweight materials that absorb visual light and emit low levels of thermal radiation, solar balloons behave similarly to hot air balloons but can ascend to much higher altitudes. Unlike hot air balloons, which use an onboard heat source to raise the temperature of the internal air, solar balloons generate heat by absorbing solar radiation, providing a free source of lift and eliminating the need for carrying an extra tank of lighter-than-air gas or fuel. The solar balloons of the present invention include mechanical vents on the tops of the balloons to store and release hot air. Using these mechanical vents, the balloons can adjust altitude to enter regions of the atmosphere with different wind flows, which can lead to horizontal controllability of the platform.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Yin, Fei
Abrégé
Methods for manipulating metabolism in astrocytes to improve astrocytic and neuronal function, as well as individual pathology hallmarks and symptoms during the development of neurodegeneration by increasing PPARa expression and activity specifically in astrocytes within the central nervous system to treat a variety of neurodegenerative conditions including but not limited to conditions involving neuronal lipid dysregulation, oxidative damage, accumulation of β-amyloid or other protein aggregates, dementia, and motor dysfunction.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Li, Peiwen
Abrégé
Examples systems including an apparatus for hydrogen production are disclosed, defining two or more reaction chambers for generating a redox reaction using a redox material. The reaction chambers are rotatable relative to a thermal or heat source for reciprocal reduction and oxidation reactions of each chamber. This differentiates the temperatures of each chamber to house different stages of thermochemical reactions for hydrogen production
C01B 3/06 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par réaction de composés inorganiques comportant un hydrogène lié électropositivement, p. ex. de l'eau, des acides, des bases, de l'ammoniac, avec des agents réducteurs inorganiques
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
F24S 20/20 - Collecteurs de chaleur solaire pour recevoir de l’énergie solaire concentrée, p. ex. récepteurs pour centrales électriques solaires
F24S 60/20 - Agencements pour l’emmagasinage de la chaleur collectée par les collecteurs de chaleur solaire utilisant des réactions chimiques, p. ex. thermochimiques ou isomérisation
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Blackwood, Erik
Glembotski, Christopher
Abrégé
Disclosed herein is a fusion peptide comprising an inactive peptide fragment of Serum/Glucocorticoid Regulated Kinase 1 (SGK1) and a cell internalization sequence, wherein the SGK1 fragment is capable of binding and sequestering glucocorticoid-induced leucine zipper (GILZ). In some embodiments, the inactive peptide fragment of SGK1 binds and sequesters GILZ, preventing it from binding and extending the half-life of endogenous SGK1. Also disclosed herein is a method for treating a disease associated with aberrant Serum/Glucocorticoid Regulated Kinase 1 (SGK1) activity in a subject that involves administering to the subject an agent that blocks the binding of endogenous SGK1 to endogenous glucocorticoid-induced leucine zipper (GILZ).
Arizona Board of Regents on Behalf of The University of Arizona (USA)
Inventeur(s)
Marty, Michael T.
Aspinwall, Craig A.
Kostelic, Marius M.
Abrégé
An electrospray needle comprising a coating inside the needle, wherein the coating is a non-conductive and non-ionizable organic material, and in some embodiments comprising a conductive outer coating; methods of making the electrospray needle, systems that use the electrospray needle, methods of detection using the electrospray needle, and a kit that includes the electrospray needle.
H01J 49/16 - Sources d'ionsCanons à ions utilisant une ionisation de surface, p. ex. émission thermo-ionique ou photo-électrique
C03C 17/00 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement
C03C 17/06 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement par des métaux
C03C 17/30 - Traitement de surface du verre, p. ex. du verre dévitrifié, autre que sous forme de fibres ou de filaments, par revêtement par des matières organiques avec des composés contenant du silicium
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Sawyer, Travis
Slomka, Bridget
Abrégé
An imaging probe includes a housing, an illumination fiber, a camera, a band-stop filter, and a sample collector. The housing has a distal tip. The illumination fiber spans between the distal tip and a proximal end of the housing, and terminates at the distal tip, such that light carried by the illumination fiber illuminates a target in front of the distal tip. The camera captures an image in a field of view that overlaps a field of illumination of the illumination fiber. The band-stop filter is between the distal tip and the camera. The sample collector collects a sample from the target. And each of the illumination fiber, the camera, the band-stop filter, and the sample collector is at least partially inside the housing.
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 10/02 - Instruments pour prélever des échantillons cellulaires ou pour la biopsie
26.
SARS-COV-2 PLPRO INHIBITORS AND METHODS OF USE THEREOF
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Thatcher, Gregory
Xiong, Rui
Shen, Zhengnan
Velma, Ganga Reddy
Indukuri, Divakar
Abrégé
5050 value down to about 0.4 nM). The potency of the disclosed PLpro inhibitors outperforms previously reported PLpro inhibitors, such as GRL0617, and non-covalent PLpro inhibitors. Pharmaceutical compositions containing the PLpro inhibitors are also described. Methods of using the PLpro inhibitors or the pharmaceutical compositions for preventing or treating diseases and/or disorders caused by a coronavirus are also described.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/421 - 1,3-Oxazoles, p. ex. pémoline, triméthadione
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 31/14 - Antiviraux pour le traitement des virus ARN
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Liang, Rongguang
Peterson, Tyler
Abrégé
All-reflective objective lens devices and methods designing such devices are described. The objective lens configurations include one or more freeform surfaces that and have high numerical apertures. An example all-reflective objective lens configuration includes at least four mirrors, where each mirror has a freeform surface, and is positioned to allow light from an object to enter objective lens configuration and reflect from each of the at least four mirrors only once before reaching a location of an aperture stop identifying an exit location objective lens configuration. The mirrors are positioned within the objective lens configuration to provide an unobscured field of view, a local optical axis of each of the mirrors is not colinear with a global optical axis of the all-reflective objective lens configuration, and the aperture stop is not positioned internal to the all-reflective objective lens configuration.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
GlycoSurf, Inc. (USA)
Inventeur(s)
Loy, Douglas A.
Hogan, David
Maier, Raina M.
Babst-Kostecka, Alicja
Perez, Susan
Boxley, Chett
Stolley, Ryan
Abrégé
The present invention is directed to polymers comprising glycolipids and methods for producing and using the same. In particular, the polymers of the invention comprise a polymer backbone and a plurality of glycolipid side chains. The glycolipid moieties present in polymers of the invention are metal ion complexing agents. As such, polymers described herein can be used for the remediation of aqueous solutions to remove metal ions.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Hulme, Christopher
Foley, Christopher
Abrégé
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Kim, Minkyu
Hogan, David
Maier, Raina M.
Abrégé
Dust poses a significant threat to human and environmental health. In 2015, an estimated 4.2 million deaths, as well as numerous health issues, were attributed to dust. Unlike other major contaminant transport pathways (e.g., water, soil, biota), atmospheric transmission is relatively unobstructed, able to rapidly transport large masses of materials over long distances and broadly impact areas downwind on local to global scales. Accordingly, dust affects global biogeochemical cycles, pollutes water bodies and air masses, and impacts global climate. Therefore, developing innovative, environmentally-compatible technologies capable of mitigating dust emissions is crucial to protect human and environmental health from mining related dust. The present invention features a method for suppressing dust from a substrate surface, said method comprising applying an effective amount of dust suppressant composition to said substrate surface, wherein said dust suppressant composition comprises an aqueous solution of a glycolipid.
C09K 3/22 - Substances non couvertes ailleurs pour abattre la poussière ou pour l'absorber
E21F 5/06 - Fluides employés pour la pulvérisation
31.
AUTOMATED IDENTIFICATION OF THE DIAGNOSTIC CRITERIA IN NATURAL LANGUAGE DESCRIPTIONS OF PATIENT BEHAVIOR FOR COMBINING INTO A TRANSPARENT DIAGNOSTIC DECISION
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Leroy, Gondy
Abrégé
A system that uses a rule-based parser and/or one or more machine learning models—e.g., a bidirectional gated recurrent unit (BiGRU) model, a hybrid bidirectional long short-term memory (BiLSTM-H) model, and/or a multilabel BiLSTM (BiLSTM-M) model, a large language model (LLM)—to label natural language sentences as indicative of diagnostic criteria used to diagnose and/or assess the severity of a mental disorder or other medical condition. In some embodiments, the system also determines whether the identified diagnostic criteria are indicative of a disorder under established medical guidelines and provides a final diagnostic label. By outputting both a diagnosis consistent with established medical guidelines and an understanding of the identified diagnostic criteria used to make that diagnosis, the disclosed system provides more clinical value to practitioners than the existing “black box” models used for medical diagnoses.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
32.
EDUCATION APPLICATION FOR RECOGNIZING EVIDENCE OF MENTAL DISORDERS BY RE-USING MACHINE LEARNING DATASETS
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Leroy, Gondy
Abrégé
An educational application that leverages gold standard data—several thousand examples of natural language sentences, extracted from electronic health records and provided by laypersons in response to surveys, describing behaviors in children indicative of autism spectrum disorder—to enable practitioners to recognize the language used by clinicians and laypersons to describe behavior indicative of autism spectrum disorder. The application provides positive examples of behaviors labeled as being indicative of one of the diagnostic criteria used to diagnose autism as well as negative examples (e.g., randomly selected from electronic health records) that are not indicative of autism spectrum disorder. Accordingly, the disclosed educational application teaches users to distinguish between relevant and non-relevant behaviors (e.g., a positive example versus a negative example), learn the accurate diagnostic criterion label (e.g., an A1 diagnostic criterion versus an A2 diagnostic criterion), and/or diagnose a case based on the combination of labels present or missing.
G16H 70/60 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des pathologies
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
33.
ENHANCING ABSORPTION OF DIETARY COMPOUNDS TO PROMOTE HEALTH
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Funk, Janet
Abrégé
Methods for enhancing the therapeutic effects of phenols comprising the oral coadministration or sequential oral administration of a phenol and glucuronidase, and compositions for enhancing the therapeutic effects of phenols.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
UNIVERSITY OF UTAH RESEARCH FOUNDATION (USA)
Inventeur(s)
Won, Youngwook
Bull, David A.
Lee, Daniel Yongwon
Abrégé
Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Tallent, Bret
Lifshitz, Jonathan
Abrégé
Dividers for small vertebrate animal cages are provided. In one aspect, a small vertebrate animal cage including a floor and a plurality of walls forming a housing area and a divider dividing the housing area into a common milieu area and two or more segregated individual nesting areas. The divider includes two or more dividing walls connected together to form an angle therebetween.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Chang, Rui
Wang, Wei
Ronaldson, Patrick T.
He, Qianying
Liu, Yanyun
Vijayan, Ramachandran
Abrégé
This invention relates generally to neurodegenerative diseases and conditions (e.g., Alzheimer's disease) characterized with dysfunctional energetic function, unregulated microglia phagocytic activity and other related de-regulated biological functions. This invention further relates to methods and compositions for treating such neurodegenerative diseases and conditions with pharmaceutical compositions comprising one or more of agents capable of protecting neurons from cell death and unregulated microglia phagocytic activity.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Watson-Hurthig, Adam
Mouneimne, Ghassan
Romanoski, Casey
Grant, Adam
Padi, Megha
Abrégé
Provided herein are compositions and methods for characterizing and treating cancer. In particular, provided herein are compositions and methods for identifying subjects with breast cancer with increased likelihood of bone metastasis and providing treatment to prevent such metastases.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
38.
ANG (1-7) DERIVATIVE OLIGOPEPTIDES AND METHODS FOR USING AND PRODUCING THE SAME
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Hay, Meredith
Konhilas, John
Polt, Robin L.
Jones, Evan
Szabo, Lajos
Abrégé
The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
UNIVERSITY OF CINCINNATI (USA)
Inventeur(s)
Deng, Zicheng
Kalinichenko, Vladimir
Shi, Donglu
Abrégé
Polymers based on a poly(β-amino) ester (PBAE) backbone are provided, with improved targeting of the lung endothelium following parenteral delivery. The disclosed polymers are polymers of a primary amine (A2), a secondary amine (A1), a diacrylate (D) and at least one end-capping hydrophilic compound (C) such as amine. The polymer is halogenated (hereinafter, halogenated PBAE polymer), preferably, fluorinated. The hydrophobic PBAE backbone is end capped with a hydrophilic compound by covalent attachment of these capping agents to the PBAE backbones via Michael Addition to form a halogenated PBAE. The disclosed polymers can be used to encapsulate/incorporate an active agent for targeted delivery to lung endothelial cells.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
The UAB Research Foundation (USA)
Inventeur(s)
Bibb, James
Umfress, Alan
Abrégé
A model and testing device for creating repetitive, rotational head trauma in rodents is disclosed herein. The testing device induces angular rotational acceleration and deceleration forces that result in injury or insult to the integrity of the intracranial tissues of the brain for the test animal and can be used to characterize, test the effects of, and/or investigate a therapeutic agent for rotational traumatic brain injury. In some embodiments, the testing device contains an animal restraint that is configured to secure the animal therein, while allowing the animal's head to rotate about the coronal plane during and following impact. The testing device can include an animal restraint, a restraint mount, configured to receive the animal restraint, a helmet assembly attached to the subject restraint mount, such that the helmet assembly is in pivotal rotation about a central axis of rotation, a pendulum arm, and an impact fixture.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Pyun, Dong Chul
Norwood, Robert
Njardarson, Jon
Qureshi, Haziq
Kleine, Tristan
Carothers, Kyle
Abrégé
A composition includes a polymer that is a reaction product of a co-monomer and one or more of elemental sulfur or a chalcogenide halide, wherein the co-monomer includes a vinyl monomer, isopropenyl monomer, acryl monomer, methacryl monomer, unsaturated hydrocarbon monomer, epoxide monomer, thiirane monomer, alkynyl monomer, diene monomer, butadiene monomer, isoprene monomer, norbornene monomer, amine monomer, thiol monomer, sulfide monomer, alkynyl unsaturated monomer, nitrone monomer, aldehyde monomer, ketone monomer, ethylenically unsaturated monomer, styrenic monomer, or a mixture of any two or more thereof; and the co-monomer comprises one or more deuterium atoms.
G02B 1/04 - Éléments optiques caractérisés par la substance dont ils sont faitsRevêtements optiques pour éléments optiques faits de substances organiques, p. ex. plastiques
COLOR ENHANCING OPTICAL LIGHT PROPAGATORS, OPTICAL FILMS, COLOR ENHANCING FILMS, AND FILM ASSEMBLIES, ARTICLES CONTAINING THE SAME, AND METHODS FOR PREPARING THE SAME
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Fathi, Zakaryae
Simmons, Joseph H.
Beyer, Wayne F.
Heineck, David
Potter, Barrett George
Simmons Potter, Kelly
Abrégé
An optical light propagator is provided, having a core formed of a high-κ dielectric material capable of transmitting wavelengths in the UV-visible range, and an outer coating on the core wherein the outer coating is formed of a low- κ dielectric material; wherein the outer coating has a plurality of porosities along the optical light propagator, wherein each of the plurality of porosities transits from an outer surface of the outer coating to an outer surface of the core at an interface between the outer coating and the core, such that wavelengths transmitted through the core of the optical light propagator are emitted through each of the plurality of porosities along the optical light propagator, and fibers, sheets, yarns, and articles made therefrom.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Fink, Wolfgang
Tarbell, Mark
Abrégé
Various examples are provided related to a human-robotic mimetic haptic control framework. In one example, a method for human-robotic mimetic haptic control includes obtaining tool operation data associated with a skilled user operating a tool during execution of an application process and training a robotic system to mimic operation of the tool based upon the tool operation data. In another example, a system for human-robotic mimetic haptic control includes one or more sensor(s) that can obtain tool operation data associated with a skilled user operating a hand tool during execution of a construction process and a computing device that can train a robotic system to mimic operation of the hand tool based upon the tool operation data.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Angel, James Roger P.
Didato, Nicholas J.
Berkson, Joel
Wortley, Richard
Abrégé
A method of producing a plurality of optical components, each having a substantially equivalent optical surface, includes providing a substrate of optical material, the substrate having an optically smooth surface; providing a mandrel having an optically smooth surface of a shape that is an inverse of a shape to be imparted to the optically smooth surface of the substrate; coating the optically smooth surface of the mandrel with a mold release material; changing a temperature of at least one of the substrate or the mandrel to be at a substantially same temperature; disposing the substrate on the mandrel such that the optically smooth surface of the substrate is on the optically smooth surface of the mandrel that is coated with the mold release material; heating the mandrel and the substrate together to soften the substrate to conform the optically smooth surface of the substrate to the shape of the mandrel; cooling the mandrel and the substrate together until the substrate is sufficiently rigid to maintain the optically smooth surface of the substrate as conformed to the shape of the mandrel; removing the substrate from the mandrel to provide a first optical component of the plurality of optical components; providing at least one additional substrate of optical material, each having an optically smooth surface; and repeating at least the changing a temperature, disposing, heating and removing for each at least one additional substrate to thereby produce the plurality of optical components. A telescope includes a plurality of the optical components.
45.
METHODS FOR THE PROGNOSIS AND TREATMENT OF TEMPORAL LOBE EPILEPSY
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Weinand, Martin
Abrégé
Differential expression of specific leukocyte genes involved in canonical pathways of neuroinflammation, oxidative stress, and lipid peroxidation, GABA (γ-aminobutyric acid) inhibition, and AMPA and NMDA receptor signaling is able to predict the severity of temporal lobe epilepsy (TLE). For example, high seizure frequency-TLE is distinguished prognostically from low seizure frequency-TLE by differentially increased specific leukocyte gene expression involved in GABA inhibition and NMDA receptor signaling. Thus, high and low seizure frequency patients represent two mechanistically different forms of temporal lobe epilepsy based on leukocyte gene expression and potentially require distinct treatments.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
46.
CONTINUOUS POWER DELIVERY AND MONITORING SYSTEM FOR IMPLANTABLE DEVICES
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Gutruf, Philipp
Stuart, Tucker
Kasper, Kevin
Abrégé
The present disclosure provides a continuous power delivery system for implantable devices, including: a wearable device configured to be worn on a patient's body, the wearable device configured to communicate with a power transmitter and receive a first power signal via a first communication protocol, the wearable device including battery management circuitry to a control a charging of a battery using the first power signal and to control a discharge of the battery to generate a second power signal; the wearable device further configured to communicate the second power signal via a second communications and powering protocol; and an implant device configured to be implanted in the patient's body, the implant device configured to communicate with the wearable device and receive the second power signal via the second communications and powering protocol, the implant device include one or more implant components configured to be powered by the second power signal.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Hua, Hong
Lyu, Pengyinjie
Abrégé
Perceptual-driven foveated head-mounted display system, in which the angular pixel density decreases with an increase of field eccentricity according to a specified angular pixel density function. Minimally perceivable image artifacts and image resolution discontinuity can result optionally eliminating or limiting the need for an eyetracker or scanning mechanism. To simultaneously see a virtual image rendered by a display and a view of a real-world scene, a freeform prism is utilized as the optical combiner to merge the optical paths of the virtual image display and real-world view. Shapes of the optical surfaces of the freeform prism is controlled to yield spatially varying optical power to achieve a spatially varying angular pixel density distribution for a virtual display path. Exemplary designs yield a total field of view of over 80° while achieving a peak resolution of 2 arcminutes per pixel through a display panel of about 1900 by 1200 pixels.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Schmidt, Monica
Herman, Eliot, M.
Abrégé
Soybean, one of the world's most significant protein and oil crops, has been enhanced through genetic engineering and mutagenesis to introduce or enhance agronomic traits. Both transgenic modification and mutagenesis have shown considerable variation in phenotypes observed in crop species. The effects of these methods on soybean seed composition and gene expression were determined by subjecting stable transgenic soybean lines to mutagenesis, generating 100 mutagenized lines with altered GFP expression, which were subsequently analyzed for protein and oil content.
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
A01H 4/00 - Reproduction de plantes par des techniques de culture de tissus
C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
49.
BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Date, Abhijit
Sutar, Yogesh
Adams, Joseph S.
Abrégé
This invention is in the field of medicinal chemistry and drug delivery. In particular, the invention relates to compositions comprising bioavailability (e.g., oral and local bioavailability) enhancing ionic liquid formulations and the use thereof for treating conditions or diseases in a subject.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/133 - Amines, p. ex. amantadine ayant des groupes hydroxyle, p. ex. sphingosine
A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
50.
METHOD AND SYSTEM TO DETERMINE SURFACE SHAPES OF HELIOSTATS USING FULLY-SAMPLED STARLIGHT IMAGES
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Angel, James Roger P.
Eads, Ryker
Abrégé
A method for measuring a shape of a reflector surface of a heliostat at night using a bright star at different elevation and azimuthal settings according to an embodiment of the current invention includes setting the heliostat in fixed orientation such that aberrated and overlapping star images formed are translated due to Earth's rotation in a translation direction across the heliostat array receiver; viewing images of the bright star using a fixed array of cameras placed at or near an array receiver of the heliostat, wherein each camera of the fixed array of cameras has a large aperture lens, and simultaneous exposures are made quickly enough and repeated for long enough, so that, as they translate past the cameras, the aberrated star image is fully sampled in two dimensions, and wherein every point on the reflector surface of the heliostat appears in one or more of the recorded images as being bright from reflected starlight; and processing the recorded images from the fixed array of cameras with a data processor to obtain the surface shape by integration of the surface slopes.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
REGENTS OF THE UNIVERSITY OF MINNESOTA (USA)
Inventeur(s)
Date, Abhijit
Nielsen, Kirsten
Sutar, Yogesh
Fulton, Sophie Rose
Abrégé
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of oral bioavailability enhancing formulations of anthelmintic benzimidazole (e.g., oxfendazole) compounds. In particular, the present disclosure provides methods for treating or preventing infectious diseases with one or more oral bioavailability enhancing formulations of anthelmintic benzimidazole (e.g., oxfendazole) compounds, or pharmaceutically acceptable salts thereof, or compositions comprising the same and an additional anti-fungal agent, and pharmaceutical compositions comprising one or more oral bioavailability enhancing formulations of anthelmintic benzimidazole (e.g., oxfendazole) compounds and at least one additional anti-fungal agent.
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Vedantham, Srinivasan
Fu, Zhiyang
Tseng, Hsin Wu
Abrégé
Computed tomography image reconstruction uses neural field algorithms to reconstruct images for breast cancer screening and diagnosis. An Attenuation Field Network (AFN) uses x-ray liner attenuation coefficients that form the basis for CT images as a continuous function of imaging volume coordinates. The AFN uses a fully connected network trained on attenuation measurements, captured using a limited number of X-ray projections through an image volume, to learn a continuous function that maps each volumetric coordinate within the image volume to its respective attenuation coefficient. The AFN renders the entire attenuation field or synthesizes high-fidelity projections that are acquired or unacquired. The synthesized projections may be combined with existing projections to yield denser or complete projection data that may be used by other image reconstruction methods
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Deymier, Pierre
Runge, Keith
Abrégé
π phase jump rotation operationresult of a transformation from the target operation result of the transformation from the π phase jump rotation operationresult of the transformation from the π phase jump rotation operation.
G06N 10/20 - Modèles d’informatique quantique, p. ex. circuits quantiques ou ordinateurs quantiques universels
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
G06N 10/00 - Informatique quantique, c.-à-d. traitement de l’information fondé sur des phénomènes de mécanique quantique
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Wang, Wei
Abrégé
Exemplary materials, methods and techniques disclosed and contemplated herein generally relate to methods for synthesizing α-deuterated α-amino acids and their derivatives.
56.
BIREFRINGENT COATING TO REMOVE POLARIZATION DEPENDENT PHASE SHIFT
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Miller, Sawyer
Jiang, Linan
Pau, Stanley
Abrégé
Methods, devices and systems are described to eliminate or reduce unwanted polarization aberrations associated with interference filters. An example method for producing a polarization aberration compensator for a thin film interference filter includes obtaining a set of Mueller matrix values based on polarization measurements of the thin film interference filter over a spectral range, and generating a metric based on a difference between a compensated Mueller matrix and an identity matrix over the spectral range. The compensated matrix represents a cumulative Mueller matrix for a combination of the thin film interference filter and the polarization aberration compensator. A configuration of the polarization aberration compensator is determined based on evaluating the metric that eliminates or reduces the difference between the compensated Mueller matrix and the identity matrix over the spectral range. Configuration parameters, including thicknesses of birefringent layers, fast-axis angles and the number of birefringent layers in the compensator are obtained.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Dhar, Arun
Allnutt, F. C. Thomas
Cruz Flores, Roberto
Abrégé
The present disclosure concerns methods and compositions for inhibiting replication of viruses within an organism in need thereof. In some cases, the methods and compositions can be applicable to aquacultured organisms. The aquacultured organisms can include, but are not limited to, crustacean organisms such as shrimp.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERISTY OF ARIZONA (USA)
Inventeur(s)
Slepian, Marvin J.
Beeley, Isabel
St. Pierre, Greyson
Qamar, Sophia
Klemish, Shane
Abrégé
e.g. e.g. an anion exchange resin and a cation exchange resin. The clean dialysate can be pumped into the inlet for the dialyzing machine, or into a storage tank. Optionally, following cleaning, the levels of electrolytes are measured, if needed additional electrolytes are added to the cleaned dialysate to provide the desired levels of electrolytes in the cleaned dialysate.
B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
59.
BIO-ENGINEERED HUMAN PROSTATE GLAND AND DISEASE MODEL
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Jiang, Linan
Miranti, Cynthia
Abrégé
Microfluidic devices, organ-on-a-chip platforms (e.g. mimicking the human prostate gland), and uses thereof are described herein. The microfluidic device includes at least two layers and a porous membrane therebetween. Each layer includes a channel, and the first channel and the second channel are aligned such that a first region of a first channel overlaps with a region of the second channel, and a second region of the first channel does not overlap a second region of the second channel. A disease model using the microfluidic devices includes (i) placing a first type of cells in the first channel and (ii) flowing a first cell culture medium through the first channel. Optionally, in step (i) a second type of cells in the second channel and in step (ii) a second cell culture medium flows through the second channel. The microfluidic devices can be used in drug screening and testing.
60.
COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING NEURODEGENERATIVE DISORDERS
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Duke University (USA)
Inventeur(s)
Chang, Rui
Brinton, Roberta Diaz
Kaddurah-Daouk, Rima
Abrégé
Provided herein are compositions and methods for diagnosing, prognosing, and treating neurodegenerative diseases in a male and female subject at risk of or diagnosed with a neurodegenerative disease. In particular, provided herein are customized metabolite analyses for characterizing and treating neurodegenerative diseases in specific subject groups from a sample from said subject.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
61.
REGENERATION OF SYMMETRICAL NONAQUEOUS ORGANIC REDOX FLOW BATTERIES
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Gianetti, Thomas
Moutet, Jules
Abrégé
A method of regenerating a symmetrical redox flow battery includes: a first discharge process having a duration in which a capacity of the redox flow battery in a first polarity and comprising a membrane decreases from a first to a second capacity, the process comprising: flowing a catholyte through a catholyte compartment in the first polarity; flowing an anolyte through an anolyte compartment in the first polarity; wherein: the first polarity of the redox flow battery includes a membrane having a first face in fluid communication with the catholyte compartment and a second face in fluid communication with the anolyte compartment; and the first and the second faces of the membrane being opposing surfaces of the membrane; and a second discharge process comprising: reversing the polarity of the catholyte and anolyte compartments wherein: the redox flow battery in the second polarity exhibits an initial increased capacity compared to the second capacity from the first discharge process.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
DATA DRIVEN DIAGNOSTIC SCIENCES, INC., DBA D3SCIENCES (USA)
Inventeur(s)
Larson, Michael C.
Hennemeyer, Charles T.
Abrégé
A biopsy system for harvesting larger volumes of tissue as compared to standard core biopsy needles. The system has a needle with a lumen, an aperture disposed at the distal end of the needle and connected to the lumen, and a cutting mechanism adapted to cut tissue. When the needle is rotated after it is inserted into a target tissue, the cutting mechanism cuts from the tissue and directs the cut tissue portions into the lumen. Multi-bioimpedance measurements are used to guide a needle and direct the application of electricity for cauterizing tissue.
A61B 10/02 - Instruments pour prélever des échantillons cellulaires ou pour la biopsie
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
63.
COMPOSITIONS AND METHODS FOR DETECTION OF ABERRANT CDK5 EXPRESSION
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Bibb, James
Gupta, Priyanka
Carter, Angela
Abrégé
Improved antibodies for detection of phosphorylated RBL1, H1.5, LARP6, SUV39H1, and FAM53C have been developed. Assays using them to detect the biomarkers: P-T143 FAM53C, P-T202 LARP6, P-S988 RBL1, P-S17 H1.5, and P-S391 SUV39H1, and diagnostic and prognostic applications stemming therefrom are also provided.
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
G01N 33/537 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide avec séparation du complexe immunologique de l'antigène ou de l'anticorps non liés
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
He, Wenhua
Guha, Salkat
Abrégé
An optical beam is provided from a transmitter aperture to a receiver aperture that receives the optical beam after displacement by a path shifting component. Received initial displacement information characterizing at least one of: an initial estimate of the displacement, or an indication that the displacement is below a predetermined threshold. Received input beams each have a different spatial mode, from a set of mutually orthogonal spatial modes that include: a lowest order spatial mode, a highest order spatial mode, and one or more intermediate order spatial modes. A relative amount of each of the input beams to be included in the optical beam is determined based at least in part on: corresponding diffraction loss estimates for each of the input beams, and the initial displacement information. One of the input beams that has a largest relative amount in the optical beam is one of the intermediate order spatial modes.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Deymier, Pierre
Runge, Keith
Abrégé
Acoustic wave devices, structures and methods are described that reduce or eliminate return losses due to reflections caused by impedance mismatch. The described features and benefits are achieved without increasing the footprint of the device and improve the power budget of the acoustic wave device. An example acoustic wave device includes an input transducer, an acoustic material, and an output transducer. The acoustic material includes a number of unit cells, each having a first layer and a second layer with differing materials. Impedance values associated with the input layer, the detection layer, and/or one or both of the first layer or the second layer of the unit cells are selected to allow the input acoustic wave to propagate within the acoustic material in a first direction with substantially no backscattered acoustic waves in the opposite direction.
G01N 29/00 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet
G10K 11/00 - Procédés ou dispositifs pour transmettre, conduire ou diriger le son en généralProcédés ou dispositifs de protection contre le bruit ou les autres ondes acoustiques ou pour amortir ceux-ci, en général
H03H 9/24 - Détails de réalisation de résonateurs en matériau qui n'est ni piézo-électrique, ni électrostrictif, ni magnétostrictif
H04R 3/12 - Circuits pour transducteurs pour distribuer des signaux à plusieurs haut-parleurs
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
NORTHWESTERN UNIVERSITY (USA)
Inventeur(s)
Willomitzer, Florian
Cornwall, Patrick
Ballester, Manuel
Wang, Heming
Abrégé
Methods, devices and systems for generating shaped, synthetic light patterns based on measured optical signals are described that are subsequently processed to generate the desired synthetic fields. By combining synthetic fields with particular amplitude, phase and/or spectral values, a desired synthetic light illumination pattern can be conceived based on the measured optical signals. The synthetic fields can then be computationally propagated in time and space to understand the characteristics of the propagated light and/or characteristics of the intervening objects.
G01S 17/34 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement utilisant la transmission d'ondes continues, soit modulées en amplitude, en fréquence ou en phase, soit non modulées utilisant la transmission d'ondes continues modulées en fréquence, tout en faisant un hétérodynage du signal reçu, ou d’un signal dérivé, avec un signal généré localement, associé au signal transmis simultanément
G01S 17/88 - Systèmes lidar, spécialement adaptés pour des applications spécifiques
G01S 17/10 - Systèmes déterminant les données relatives à la position d'une cible pour mesurer la distance uniquement utilisant la transmission d'ondes à modulation d'impulsion interrompues
G01J 3/10 - Aménagements de sources lumineuses spécialement adaptées à la spectrométrie ou à la colorimétrie
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Djordjevic, Ivan B.
Nafria, Vijay
Abrégé
Entanglement is a unique quantum information processing (QIP) feature. Entanglement can be used to implement quantum sensors with improved sensitivity over classical sensors. Disclosed are systems and techniques for entanglement distribution over turbulent free-space optical (FSO) channels based on using adaptive optics. An apparatus can include a C-band tunable laser, amplifier, and periodically poled lithium niobate (PPLN) waveguide for generating entangled photon pairs. The entangled photon pairs are multiplexed with a classical laser beam and transmitted over a free-space optical (FSO) link. A reflected beam from an intermediate node, or a direct beam from a remote transmitter with line-of-sight, is received and provided to an adaptive optics (AO) system using the classical signal as a channel probe to determine a correction. The received beam is further reflected by a deformable mirror to apply the correction. The entangled photon pairs are demultiplexed from the received beam and provided to intended users.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Djordjevic, Ivan B.
Nafria, Vijay
Abrégé
Disclosed are systems and techniques for covert and/or low probability to intercept communications using thermal source-based signaling. A transmitter can generate a modulated signal by modulating a low-density parity check (LDPC)-coded modulation signal on an amplified spontaneous emission (ASE) noise source signal. The modulated signal can be amplified by one or more Erbium-Doped Fiber Amplifier (EDFA) amplification stages. A noise-masked signal can be generated by combining the modulated signal with an added noise signal from an additional EDFA, and can be transmitted to a receiver via a free-space optical (FSO) link. A receiver can apply adaptive optics (AO) corrections to the received noise-masked signal and apply a narrowband filter. The transmitted signal can be detected from the narrowband filtered signal by using a balanced detector and a local laser, wherein the balanced detector uses a beam from the local laser to perform heterodyne detection.
69.
SYSTEMS AND METHODS FOR CLOSED-LOOP ULTRASOUND AND PHOTOACOUSTIC IMAGING
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Witte, Russell
Reichel, Eric
Curiel, Clara
Salinas, Christopher
Stratton, Delaney
Abrégé
A 3D PE/PAT imaging system and probe device includes a tissue coupling interface that enables closed-loop volumetric ultrasound and photoacoustic imaging and spectroscopy that does not depend on the operator. In addition to a probe device that incorporates light and sound signals into a coaligned axis for application to a target tissue area, the imaging system includes a volumetric scanning subsystem including a motor and a housing for the motor, the motor mechanically engaged with the probe device to actuate the probe device along a linear axis associated with a surface of the target tissue area for volumetric scanning. The tissue coupling interface includes a receiver plate that can magnetically interface with a tissue coupler element positionable around the target tissue area to minimize movement of the target tissue area, allow for hands-free operation and improve reproducibility of data generated by the imaging system.
ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Papas, Klearchos
Johnson, Robert C.
Abrégé
Improved membranes for various devices including encapsulation devices and delivery devices are provided. Membranes of the present disclosure provide various combinations and layers of structures and features shown and described herein. In some embodiments, a spacing is provided between certain layers to enhance vascularization of the device. The present disclosure further provides devices for delivery of drugs, agent, and for housing cells.
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Celdran-Bonafonte, Diego
Abrégé
Surgical training devices, kits, and associated methods are disclosed. The surgical training devices include a body shaped to correspond to an animal. The surgical training devices also include an insert for removable insertion into an opening in the body. The insert can be to be covered by a cover, which can be removably attached to the insert. An entirety or majority of the body, the insert, and the cover can be formed of materials sourced from sources other than the animal.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Sun, Daekyu
Abrégé
Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). The present invention reveals that quinacrine directly binds to G4 RNAs found in genomic RNA of the COVID-19 virus, showing antiviral activity against COVID-19 using in vitro cell culture systems. An object of the present invention is thus a new pharmaceutical composition of quinacrine for the treatment of COVID-19. Another object of the invention is a method for administering quinacrine by various routes specifically for treatment, including oral administration, sterile intravenous injection, and others.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
73.
METHODS AND COMPOSITIONS FOR TREATING CANCERS AND OTHER PROLIFERATIVE DISORDERS
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Rafikova, Olga
Rafikov, Ruslan
Abrégé
Inositol monophosphatase 1 (IMPA1) controls the activity of the primary cell proliferation signaling cascades activated through the inositol-dependent phosphorylation of Akt and PKCs. Furthermore, IMPA1-mediated control of cell proliferation involves the recruitment of cytosolic IMPA1 on a plasma membrane by the receptor for advanced glycation endproducts (RAGE). Interaction between IMPA1 and RAGE redistributes inositols from the cytosolic pool to membrane microdomains and amplifies the synthesis of membrane-bound phosphatidylinositols (PtdIns) to trigger inositol-dependent cell proliferation. Thus, the peptide compositions described herein inhibit the formation of the complex between IMPA1 and RAGE (e.g., a pathogenic complex) to control over-proliferative cells.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Fard, Erfan M.
Norwood, Robert A.
Koch, Thomas L.
Pau, Stanley K.
Abrégé
An optical arrangement includes an optical printed circuit board (OPCB) having at least a first optical waveguide having a first end located on the OPCB. The optical arrangement also includes at least one photonic integrated circuit (PIC) mounted to the OPCB. The PIC includes a second optical waveguide. The first waveguide has a second end located on a portion of the second waveguide to optically couple light between the PIC and the first waveguide. The portion of the second waveguide on which the second end of the first waveguide is located has an inverse taper. The inverse tapered portion is defined by a plurality of segments. The segments of the inverse tapered portion each have a length and a taper rate that causes each segment to make an equal contribution to any radiation losses in the mode transformation of light being coupled between the first and second waveguides.
G02B 6/12 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
G02B 6/126 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré utilisant des effets de polarisation
ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Papas, Klearchos
Johnson, Robert C.
Abrégé
Methods and systems of preserving, treating and monitoring organs, tissues and implants are provided. In some embodiments, systems are provided that comprises a closed terminus and a substantially sealed system and wherein a parameter is detected in order to selectively control a flow of fluid to the system. Methods and system for preserving organs are provided with reduced material needs, improved energy efficiencies, and enhanced organ preservation are provided.
76.
THREE-DIMENSIONAL (3D) PRINTING OF ANISOTROPIC MATERIAL
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Pau, Stanley
Abrégé
Methods and print head configurations for fabrication of complex three-dimensional (3D) structures using anisotropic materials are described. One example 3D print head includes a tubular channel configured to receive an anisotropic material, and to allow the anisotropic material to move therein, and a chamber configured to heat the anisotropic material. The 3D print head also includes one or more electrodes positioned to at least partially surround a section of the tubular channel, where the one or more electrodes are configured to receive one or more voltages to establish an electric field across the tubular channel, and the one or more voltages are selectable to allow the electric field having a magnitude and direction to be established across the tubular channel.
77.
SUPERSONIC JET CURTAINS FOR CONTROL OF MOMENTS AND FORCES ON AIRCRAFT
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
CALIFORNIA INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Wygnanski, Israel
Taubert, Lutz
Graff, Emilio
Gharib, Morteza
Abrégé
Conventional moving control surfaces on a typical tailless aircraft are replaced with sweeping Jet Actuators ("SJAs") for Active Flow Control ("AFC"). However, a large quantity of SJAs may be necessary in each array and efficacy of SJAs has only been demonstrated at low speeds (i.e., Mach 0.2 or less). In this disclosure, Supersonic Steady Jets (SSJs) are used as control surface replacements for aircraft. The SSJs are distributed on the aircraft in locations and orientations that take into consideration changing local flow conditions on the surface of the aircraft. In one example, when a single SSJ was used to control the pitch of the aircraft, the single SSJ increased the trimmed lift of the aircraft almost as well as an array of SJAs, while providing better yaw control at a small accompanying rolling moment.
78.
PEPTIDES FOR THE TREATMENT OF SARS-COV, PULMONARY HYPERTENSION, AND OTHER PULMONARY VASCULAR DISEASES
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
James, Joel
Rafikov, Ruslan
Abrégé
Several novel peptides to block various signaling domains of APN are disclosed. The peptides disclosed interrupt the action of APN (aminopeptidase N peptide) for the treatment of viral (i.e. covid) infections and PAH. The interruption is specifically accomplished by binding an antagonist/inhibitor (i.e. peptide, antibody, small molecule) to the intracellular portion of the APN.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Apai, Daniel
Cuello, Joel L.
Abrégé
A system including a combination of a photobioreactor fluidly coupled to a particle filtration system is provided. Also provided are methods of cultivating Coccolithophores in the system, which can be used to capture carbon dioxide in the culture medium into calcium carbonate.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Gutruf, Philipp
Stuart, Tucker
Abrégé
The present disclosure provides a wearable article including a 3D printed base, 3D printed antenna ground plane structure and a 3D printed a dipole antenna structure, wherein the base, ground plane structure and dipole antenna structure comprises a 3D printed mesh which is formed of a stretchable elastomeric polymer material. The wearable article also includes signal transmission and power harvesting circuitry comprising duplexing circuit to transmit and receive data and to receive wireless power from a power transmission unit.
81.
METHODS OF TREATING DILATED CARDIOMYOPATHY AND HEART FAILURE
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Reed, Guy
Gladysheva, Inna
Sullivan, Ryan
Abrégé
Methods for treating, ameliorating and/or preventing progression of cardiomyopathy and heart failure by drugs that reduce or inhibit Factor XII and/or activated Factor XII (collectively FXII(a)), diagnosing, and/or screening for Factor Xll(a)-inhibiting/suppressing drugs for heart failure and/or cardiomyopathy by detecting biomarkers selected from a group consisting of one or more of plasma renin activity (PRA), soluble pro-renin receptor (s(P)RR) and/or coagulation Factor XI la (FXII(a)). Reduction of Factor Xll(a) levels and/or activity is effective for treating, ameliorating and/or preventing progression of cardiomyopathy and/or heart failure in the subject.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Lima, Natzem
Sawyer, Travis
Abrégé
A polarimetric endoscope includes an insertion tube and a polarization imaging channel. The polarization imaging channel includes (i) an imaging fiber bundle having a plurality of optical fibers and being at least partially in the insertion tube, (ii) an imaging lens at a distal tube-end, of the insertion tube, that forms an image at a distal bundle-end of the imaging fiber bundle, and (iii) a polarizer array having a plurality of polarizers each aligned to a distal end of a respective one of the plurality of optical fibers and transmitting one of a plurality of polarization states. Each of the imaging fiber bundle and the first and second illumination channels is at least partially in the insertion tube.
G02B 23/26 - Instruments pour regarder l'intérieur de corps creux, p. ex. endoscopes à fibres utilisant des guides de lumière
G02B 27/28 - Systèmes ou appareils optiques non prévus dans aucun des groupes , pour polariser
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
A61B 1/07 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement utilisant des moyens conduisant la lumière, p. ex. des fibres optiques
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Carew, Jennifer
Nawrocki, Steffan
Wang, Wei
Abrégé
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a tetrahydroacridine (or similar) structure, an acridine (or similar) structure, a benzonaphthyridine (or similar) structure, or a tetrahydrobenzonaphthyridine (or similar) structure which function as autophagy inhibitors and/or histone deactylase inhibitors, and their use as therapeutics for the treatment of conditions characterized with aberrant autophagy activity and/or aberrant HDAC activity (e.g., cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, aging, heart disease, rheumatoid arthritis, infectious discuses, conditions and symptoms caused by a viral infection (e.g., COVID-19)).
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Fernandez, Fabian
Grandner, Michael
Mason, Brooke Jordan
Pau, Stanley K. H.
Abrégé
Methods and devices are described that relate to eyewear that are specifically designed to allow emissions of circadian-active green light to reach the observer. An example wearable device includes one or more windows positioned to allow light from a light source to propagate toward a position of a wearer's eyes. and a spectral filter that comprises a coating positioned on one or more sections of the one or more windows. The spectral filter includes a multi-layer stack of dielectric material with alternate high and low indices of refraction. The number thicknesses of the layers are selected to provide designed transmission and blocking characteristics to allow circadian-active spectra to pass through while blocking spectral content other than the circadian-active spectra. The filter characteristics include one contiguous transmission region to transmit 98%-100% of a precisely-selected green region and two contiguous blocking regions that block 80-100% of the remaining spectral content.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Vedantam, Gayatri
Viswanathan, V.K.
Roxas, Bryan
Abrégé
Infectious diseases pose persistent threats to the health and wellbeing of humans and animals globally. Systems and methods for multi omics-based validation of gene expression data have been developed. The methods assess disease/infection/immunity data and identify treatment regimens most likely to yield beneficial patient outcomes. The methods are implemented in a computational program for integrated, queryable pathogen/host atlas of CDC “Urgent Threat” Pathogens. Methods of treatment for disease/infection/immunity using active agents according to the described methods are also provided. In some forms, the systems and methods determine optimal treatment regimens for subjects infected with Clostridioides difficile, or Neisseria gonorrhoeae. Exemplary subjects include farm animals and humans.
G16B 25/00 - TIC spécialement adaptées à l’hybridationTIC spécialement adaptées à l’expression de gènes ou de protéines
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
86.
PLANET ATMOSPHERE GASES ENWRAPPED INTO COMPOSITE NANOMATERIALS WITH MEDICAL TREATMENT APPLICATIONS
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
HONORHEALTH RESEARCH & INNOVATION INSTITUTE (USA)
Inventeur(s)
Zenhausern, Frederic
Russell, Joellen L.
Gordon, Michael
Sowinski, Marta
Moser, Justin
Harris, Ashlee
Zhao, Zhu
Barrett, Matthew
Abrégé
Provided are methods of treating a biological system with a gas marble, including related methods of making a gas marble from an identified gaseous chemical compound from a planetary source, including a planetary atmosphere. The collected gaseous chemical compound can be activated with a liquid having an assembly of composite nanomaterials to form stable gas marbles that are, in turn, used with a treatment method. Also provided are stable marbles gases useful in applications related to biological systems, including health-related applications by medical gas therapy.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Zenhausern, Frederic
Fattahi, Ali
Lacombe, Jerome
Abrégé
Provided herein are devices for self-testing for a plurality of biomarkers from a liquid biofluid sample. and related methods of using the devices to test for the biomarkers presence or absence. The devices comprise a specially configured vertical flow biosensor to provide a device platform that is safe and can be used at-home/in the field without need for any specialized equipment or external power sources.
Arizona Board of Regents on Behalf of the University Of Arizona (USA)
Inventeur(s)
Guha, Saikat
Gagatsos, Christos
Lukens, Joseph
Abrégé
Generation of a non-Gaussian quantum state uses a quantum optical frequency comb source comprising at least one nonlinear optical medium and providing spectral modes including a plurality of pairs of entangled spectral modes, each pair including: a first spectral mode centered at a first frequency, and a second spectral mode entangled with the first spectral mode and centered at a second frequency that is spaced from the first frequency at a multiple of the frequency-bin spacing. Electrically controllable optical transformation modules are connected in series with a first module receiving the spectral modes. Two or more of the modules each comprise: a spectral mode phase shifter applying respective phase shifts to different spectral modes based on at least a first electrical signal, and a spectral mode mixer coupled to the spectral mode phase shifter and coupling spectral modes centered at different frequencies based on at least a second electrical signal.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Fan, Linran
Chen, Pao-Kang
Abrégé
The adaptive methodology of (purposefully, intentionally aperiodically) poling of an optical waveguide made in a nonlinear material substrate to achieve a continuous increase of overall nonlinear conversion efficiency with increase in the length of such waveguide. As a result of such poling, the variation of at least a waveguide thickness is compensated by adjusting the poling period along the waveguide to match the local momentum difference of the nonlinear process. For a second-harmonic generation, a near-ideal performance of the nonlinear energy conversion process was demonstrated even for a 21 mm long waveguide (with the SHG efficiency as high as 9415%/W and a 82.6% absolute power conversion efficiency). The adaptive poling methodology can also be applied to compensate other systematic inhomogeneity of a WG device in, for example, etching depth, diffusion depth, dose of lithographic exposure of the nonlinear material, and doping density across the nonlinear material substrate.
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Mason, Brooke Jordan
Fernandez, Fabian
Grandner, Michael
Pau, Stanley K. H.
Abrégé
Methods and devices are described that relate to spectral filters and associated eyewear that are specifically designed to block emissions of circadian-active blue light to reach the observer. An example wearable device that includes one or more windows, and a spectral filter that comprises a coating positioned on one or more sections of the one or more windows. The spectral filter includes a multi-layer stack of dielectric material with alternate high and low indices of refraction. The number of the layers and a thickness of each layer are selected to provide designed transmission and blocking characteristics to block circadian-active spectra while allowing spectral content outside of the circadian-active spectra to pass through the spectral filter. The spectral filter further includes an additional layer to effectuate a particular color such as the color pink.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Margolis, David
Bieg, Mckenzie
Bosset, Mark
Perez, Dania
Shahin, Timor
Smith, Evan
Utzinger, Urs
Abrégé
A surgical self-retaining retractor system includes a self-retaining retractor having first and second tissue engaging members that oppose one another and maintain an opening in an incision. First and second force sensors are respectively coupled to the first and second tissue engaging members such that the force sensors detect force being exerted thereon by tissue when the self-retaining retractor is maintaining an opening through the incision.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Takashima, Yuzuru
Abrégé
An optical system for modulating a light beam emitted by a laser light source. The system includes a phase light modulation device positioned to receive the laser light beam, a 4f relay optics positioned to receive light emitted from the phase light modulation device, and having a tilt mirror positioned in the light path, the tilt mirror having a center hole that permits light to pass therethrough and relay to a focusing lens, whereby a modulated and linearly polarized beam is transmitted; a quarter wave plate having a polarized beam splitter positioned to receive the modulated and linearly polarized beam; and a digital micromirror device that includes an array of micromirrors and that modulates amplitude of light in a pixelated manner by redirecting light into two directions, on- and off-directions, by electrically controlling the tilt angle of each micromirror.
G02B 26/02 - Dispositifs ou dispositions optiques pour la commande de la lumière utilisant des éléments optiques mobiles ou déformables pour commander l'intensité de la lumière
G01S 7/481 - Caractéristiques de structure, p. ex. agencements d'éléments optiques
G02B 27/28 - Systèmes ou appareils optiques non prévus dans aucun des groupes , pour polariser
93.
INTERFACE AND CONTROL OF UNDERWATER ROBOTICS, INSTRUMENTS, AND SENSORS FROM A HUMAN OCCUPIED SUBMERGED SPACE
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Lombardi Undersea LLC (USA)
Inventeur(s)
Burleson, Winslow
Lombardi, Michael
Abrégé
A networked system architecture including hardware and software elements permits data transmission between underwater systems. The network architecture includes data transmission between underwater computers, instruments, robotic vehicles, human-occupied underwater habitats, and/or worn sensor devices. Data is transmitted over wired communication channels, wireless communication channels, or a combination thereof. The network is established independent of surface connectivity (e.g., a topside connection) and creates a Local Area Network (LAN) or Wide Area Network (WAN) specific to an underwater environment. A system administrator, such as a diver, operates an underwater and waterproof computer to control and operate an underwater and waterproof device (e.g., a robotic vehicle) over the LAN/WAN. The underwater device may be a remotely operated vehicle (ROV), an autonomous underwater vehicle (AUV), a drifting sensor, a moored sensor, or the like.
G05B 19/4155 - Commande numérique [CN], c.-à-d. machines fonctionnant automatiquement, en particulier machines-outils, p. ex. dans un milieu de fabrication industriel, afin d'effectuer un positionnement, un mouvement ou des actions coordonnées au moyen de données d'un programme sous forme numérique caractérisée par le déroulement du programme, c.-à-d. le déroulement d'un programme de pièce ou le déroulement d'une fonction machine, p. ex. choix d'un programme
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Inventeur(s)
Walker, Christopher K.
Abrégé
A large balloon reflector, capable of launching and support itself at high altitudes, with a feed system capable of steering the beam quickly enough to perform target tracking of fast-moving terrestrial, stratospheric, or orbiting objects. The large balloon reflector antenna forms a suborbital antenna system that is suitable for operation from radio to infrared wavelengths and can be used, for example, for remote sensing of objects on the ground, in the atmosphere, or in space.
B64U 101/00 - Véhicules aériens sans pilote spécialement adaptés à des utilisations ou à des applications spécifiques
G01C 21/16 - NavigationInstruments de navigation non prévus dans les groupes en utilisant des mesures de la vitesse ou de l'accélération exécutées à bord de l'objet navigantNavigation à l'estime en intégrant l'accélération ou la vitesse, c.-à-d. navigation par inertie
H01Q 15/16 - Surfaces réfléchissantesStructures équivalentes courbes suivant deux dimensions, p. ex. paraboloïdales
Arizona Board of Regents on Behalf of the University of Arizona (USA)
THE UNIVERSITY OF SOUTHERN MISSISSIPPI (USA)
Inventeur(s)
Brown, Judith K.
Mondal, Mosharrof Hossain
Paredes Montero, Jorge Rafael
Flynt, Alex
Abrégé
Provided herein are synthetic RNAs comprising a piRNA sequence and a target sequence for a gene of interest. The synthetic RNAs find use in methods of gene editing, in particular in methods of silencing expression of the gene of interest.
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Chapman, Eli
Zerio, Christopher
Abrégé
The present invention features inhibitors of the eIF4A enzyme. These inhibitors have a novel mechanism for inhibiting the eIF4A enzyme by occupying a binding pocket within the eIF4A RNA-binding groove, thereby perturbing RNA binding, blocking ATP hydrolysis, and, consequently, inhibiting RNA helicase activity. Thus, the compounds of the present invention are RNA-competitive, ATP-uncompetitive elF4A inhibitors that directly bind elF4A and inhibit the protein.
C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
97.
OPTICAL SYSTEM, LASER SPOT POSITION DETERMINATION PROCESS, AND CALIBRATION PROCESS FOR DETERMINISTICALLY SHAPING SUBSTRATES USING LASER PULSES
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Chalifoux, Brandon
Arnold, Ian
Laverty, Kevin
Abrégé
Methods for determining laser pulse positions for shaping an optical element may comprise: determining a stress field for at least a portion of a substrate, wherein the stress field comprises at least three components of stress, wherein the stress field comprises a plurality of stress states for the at least a portion of the substrate; determining, based at least on the stress field and a calibration model, a spot density over the at least a portion of the substrate; determining, based on the spot density, a laser spot position allocation that arranges a number of laser pulses into a minimum number of lines that achieves the spot density; and causing, based on the laser spot position allocation, output of a machine program that coordinates a rotation stage, beam shaping, a translation stage, and a laser firing parameter for surface shaping of the at least a portion of the substrate.
B23K 26/50 - Travail par transmission du faisceau laser à travers ou dans la pièce à travailler
B23K 26/0622 - Mise en forme du faisceau laser, p. ex. à l’aide de masques ou de foyers multiples par commande directe du faisceau laser par impulsions de mise en forme
B23K 26/08 - Dispositifs comportant un mouvement relatif entre le faisceau laser et la pièce
B23K 103/00 - Matières à braser, souder ou découper
G01L 5/16 - Appareils ou procédés pour la mesure des forces, du travail, de la puissance mécanique ou du couple, spécialement adaptés à des fins spécifiques pour la mesure de plusieurs composantes de la force
98.
PHENYLLACTIC ACID COMPOSITIONS AND RELATED METHODS OF USE
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Herbst-Kralovetz, Melissa
Date, Abhijit
Laniewski, Pawel
Sutar, Yogesh
Abrégé
This invention is in the field of medicinal chemistry. In particular, the invention relates to compositions comprising phenyllactic acid, and related methods for treating, preventing, and/or ameliorating symptoms and/or conditions characterized with microbiome dysbiosis (e.g., sexually transmitted infections, urinary tract infections, bacterial vaginosis).
99.
DRUGGABLE FORMULATION FOR MU/DELTA OPIOID ANTAGONIST FOR ENHANCING PAIN THERAPY AND TREATMENT OF OPIOID WITHDRAWAL
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Streicher, John, M.
Polt, Robin, L.
Alabsi, Wafaa
Szabo, Lajos, Z.
Tanguturi, Parthasaradhireddy
Abrégé
Methods and compositions related to mu/delta opioid receptor heterodimer (MDOR) antagonists, including novel compositions and modifications thereof and thereto. These novel methods and compositions may enhance the beneficial effects of MDOR antagonists as compared to MDOR antagonists that are formulated differently or that are unmodified. These compositions and methods may be used (including when used concomitantly with opioid agonist-based therapy) to: enhance the antinociceptive and/or analgesic effects of opioid therapy, to reduce the side effects and/or adverse effects of opioid therapy, and/or to treat opioid dependence.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Lee, Jaeheon
Wu, Jiajia
Abrégé
Methods are disclosed for leaching metal-containing materials, such as those contained in the cathode of spent lithium-ion batteries, using a leach solution of an amino acid and a reducing agent. The metal-containing material is treated with the leach solution to recover at least one metal. For example, when the metal-containing material is lithium cobalt (III) oxide (LiCoO2), leaching with the leach solution of the present invention enables the recovery of the lithium and/or cobalt metal.